Current status and future challenges of HPV preventive vaccine of cervical cancer

Abstract

Human papillomavirus (HPV) vaccine is approved by the the U. S. Food and Drug Administration in 2006 for female cancer prevention. There are currently three types of prophylactic HPV vaccines, and its application in developed countries can significantly reduce HPV infection rates and cervical lesion rates. In developing countries, HPV vaccination rates are low due to lack of knowledge of cervical cancer and funds. At the same time, concerns about vaccine safety have led to a reduction in vaccination rates in developed countries. Countries are facing the challenge of increasing vaccination rates. Key words: Papillomaviridae; Uterine cervical neoplasms; Papillomavirus vaccines; Primary prevention